Patents by Inventor Walter J. Koch
Walter J. Koch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230073246Abstract: Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.Type: ApplicationFiled: October 5, 2022Publication date: March 9, 2023Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Arthur M. Feldman, Douglas G. Tilley, Weizhong Zhu, Kamel Khalili, Walter J. Koch
-
Patent number: 11542555Abstract: Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.Type: GrantFiled: May 21, 2020Date of Patent: January 3, 2023Assignee: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Arthur M. Feldman, Douglas G. Tilley, Weizhong Zhu, Kamel Khalili, Walter J. Koch
-
Patent number: 11235029Abstract: The present invention relates to compositions and methods for the treatment of heart failure.Type: GrantFiled: March 9, 2018Date of Patent: February 1, 2022Assignees: Temple University-Of The Commonwealth System of Higher, Education Johns Hopkins Technology Ventures, Universita di Napoli Federico IIInventors: Alessandro Cannavo, Ning Feng, Giuseppe Rengo, Nazareno Paolocci, Walter J. Koch
-
Patent number: 11236389Abstract: Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.Type: GrantFiled: January 30, 2015Date of Patent: February 1, 2022Assignee: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Arthur M. Feldman, Douglas G. Tilley, Weizhong Zhu, Kamel Khalili, Walter J. Koch
-
Publication number: 20210017600Abstract: Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.Type: ApplicationFiled: May 21, 2020Publication date: January 21, 2021Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Arthur M. Feldman, Douglas G. Tilley, Weizhong Zhu, Kamel Khalili, Walter J. Koch
-
Patent number: 10835620Abstract: This invention is generally related to novel compositions for treating or preventing heart failure. Specifically, the disclosure provides a composition comprising an amino-terminal domain of Beta.adrenergic receptor kinase-1 (Beta.ARKnt) peptide, or a nucleic acid encoding Beta.ARKnt. Further disclosed are methods of using the compositions for treating or preventing heart failure in a subject or for altering Beta.-adrenergic receptor (Beta.AR) density in a subject.Type: GrantFiled: June 5, 2017Date of Patent: November 17, 2020Assignee: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Walter J. Koch, Sarah M. Schumacher-Bass
-
Patent number: 10172907Abstract: The invention concerns the contribution of elevated levels of circulating alsosterone to heart disease and other hyperaldosteronic conditions. Since activation of ?-arrestin 1(?arr1) by the Angiotensin II (AngII) type 1 receptor (AT1R) mediates AngII-induced aldosterone production, ?-arrestin 1(?arr1) is a therapeutic target for heart disease. The invention provides a ?arr1 protein fragment comprising the C-terminus of ?arr1 (?arr1ct; SEQ ID NO:3), compositions containing this protein fragment, and methods of using this protein fragment to reduce elevated levels of aldosterone in heart disease and other hyperaldosteronic conditions by inhibition of ?-arrestin 1(?arr1). These compositions and methods are of therapeutic benefit in chronic heart failure and progression to heart failure after myocardial infarction (MI).Type: GrantFiled: October 5, 2011Date of Patent: January 8, 2019Assignees: NOVA SOUTHEASTERN UNIVERSITY, THOMAS JEFFERSON UNIVERSITYInventors: Anastasios Lymperopoulos, Walter J. Koch
-
Publication number: 20180256683Abstract: The present invention relates to compositions and methods for the treatment of heart failure.Type: ApplicationFiled: March 9, 2018Publication date: September 13, 2018Inventors: Alessandro Cannavo, Ning Feng, Giuseppe Rengo, Nazareno Paolocci, Walter J. Koch
-
Publication number: 20170016066Abstract: Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.Type: ApplicationFiled: January 30, 2015Publication date: January 19, 2017Applicant: Temple University of the Commonwealth System of Higher EducationInventors: Arthur M. FELDMAN, Douglas G. TILLEY, Weizhong ZHU, Kamel KHALILI, Walter J. KOCH
-
Publication number: 20130274191Abstract: The disclosure describes the contribution of elevated levels of circulating alsosterone to heart disease and other hyperaldosteronic conditions. Since activation of beta-arrestin I (beta.arr-1) by the Angiotensin II (AngII) type 1 receptor (AT1R) mediates AngII-induced aldosterone production, beta-arrestin I (beta.arr-1) is a therapeutic target for heart disease. Specifically, the disclosure provides a beta.arr-1 protein fragment comprising the C-terminus of beta.arr-1 (beta.arr1ct; SEQ ID NO:3), compositions containing this protein fragment, and methods of using this protein fragment to reduce elevated levels of aldosterone in heart disease and other hyperaldosteronic conditions by inhibition of beta-arrestin (beta.arr-1). These compositions and methods are of therapeutic benefit in chronic heart failure and progression to heart failure after myocardial infarction (MI).Type: ApplicationFiled: October 5, 2011Publication date: October 17, 2013Applicants: THOMAS JEFFERSON UNIVERSITY, NOVA SOUTHEASTERN UNIVERSITYInventors: Anastasios Lymperopoulos, Walter J. Koch
-
Patent number: 8383601Abstract: The invention provides nucleic acid segments, compositions and methods for the treatment of heart failure, vascular dysfunction, endothelial dysfunction, diabetes, [Ca2+]i regulation and NO synthase dysfunction. Adeno-associated and adenovirus are used as gene delivery vectors for the nucleic acid segments to product long term over-expression of S100A1, a small calcium sensing protein associated with the disclosed ailments and dysfunctions.Type: GrantFiled: October 30, 2007Date of Patent: February 26, 2013Assignee: Thomas Jefferson UniversityInventors: Walter J. Koch, Patrick Most, Sven T. Pleger, Joseph E. Rabinowitz
-
Publication number: 20100190840Abstract: The invention provides nucleic acid segments, compositions and methods for the treatment of heart failure, vascular dysfunction, endothelial dysfunction, diabetes, [Ca2+]i regulation and NO synthase dysfunction. Adeno-associated and adenovirus are used as gene delivery vectors for the nucleic acid segments to product long term over-expression of S100A1, a small calcium sensing protein associated with the disclosed ailments and dysfunctions.Type: ApplicationFiled: October 30, 2007Publication date: July 29, 2010Applicant: THOMAS JEFFERSON UNIVERSITYInventors: Walter J. Koch, Patrick Most, Sven T. Pleger, Joseph E. Rabinowitz
-
Publication number: 20100048479Abstract: The present invention relates to compositions and methods for the treatment of failing hearts. More specifically, the present invention provides for the inhibition of G-protein coupled receptor kinase 2 activity in the adrenal gland, which, for example, decreases catecholamine secretion and the sympathetic burden of the failing heart, thereby improving the cardiac adrenergic/inotropic reserve and overall contractile function.Type: ApplicationFiled: November 9, 2007Publication date: February 25, 2010Applicant: THOMAS JEFFERSON UNIVERSITYInventors: Anastasios Lymperopoulos, Walter J. Koch
-
Publication number: 20090053696Abstract: The present invention relates, in general, to heart failure, and, in particular, to a method of evaluating heart failure patients by monitoring ?-adrenergic receptor kinase (?ARK1) levels in lymphocytes from such patients.Type: ApplicationFiled: November 4, 2005Publication date: February 26, 2009Inventors: Walter J. Koch, Guido Iaccarino
-
Patent number: 7060871Abstract: The present invention deals with gene therapy for treating chronic heart failure and other cardiac disease states which are accompanied by a reduced number or functioning of myocardial beta-adrenergic receptors (?-AR). ?-AR receptor function is augmented in transgenic animals by delivery and expression of a beta-2-adrenergic receptor gene or a gene encoding a beta adrenergic receptor kinase inhibitor, resulting in increased in vivo left ventricular function. The present invention includes recombinant plasmid vectors, alternative beta-adrenergic receptor gene delivery strategies, and transgenic mice carrying a ?-AR transgene, a ?-ARK transgene, or a ?-ARK inhibitor transgene.Type: GrantFiled: June 28, 2002Date of Patent: June 13, 2006Assignee: Duke UniversityInventors: Walter J. Koch, Robert J. Lefkowitz, Carmelo A. Milano, Howard A. Rockman
-
Patent number: 6964984Abstract: Desensitization of receptors that control disease is prevented by inhibiting G-protein receptor kinases. This has applicability, e.g., for patients with heart failure or on a left ventricular heart device or a heart pump after surgery or about to undergo surgery and at high risk for a cardiac event or on an opiate or addicted to opiate or with cystic fibrosis or rheumatoid arthritis.Type: GrantFiled: June 30, 2003Date of Patent: November 15, 2005Assignee: Duke UniversityInventors: Jonathan S. Stamler, Robert J. Lefkowitz, Erin J. Whalen, Walter J. Koch, Claude A. Piantadosi
-
Publication number: 20040053852Abstract: Desensitization of receptors that control disease is prevented by inhibiting G-protein receptor kinases. This has applicability, e.g., for patients with heart failure or on a left ventricular heart device or a heart pump after surgery or about to undergo surgery and at high risk for a cardiac event or on an opiate or addicted to opiate or with cystic fibrosis or rheumatoid arthritis.Type: ApplicationFiled: June 30, 2003Publication date: March 18, 2004Inventors: Jonathan S. Stamler, Robert J. Lefkowitz, Erin J. Whalen, Walter J. Koch, Claude A. Piantadosi
-
Patent number: 6683057Abstract: The present invention relates, in general, to vascular smooth muscle proliferation and, in particular, to a method of inhibiting arterial and venous smooth muscle proliferation resulting, for example, from arterial injury or vein grafting. The invention also relates to an expression construct encoding a G&bgr;&ggr; inhibitor suitable for use in such a method.Type: GrantFiled: September 21, 1999Date of Patent: January 27, 2004Assignee: Duke UniversityInventors: Walter J. Koch, Robert J. Lefkowitz, Per-Otto Hagen
-
Patent number: 6627602Abstract: Desensitization of receptors that control disease is prevented by inhibiting G-protein receptor kinases. This has applicability, e.g., for patients with heart failure or on a left ventricular heart device or a heart pump after surgery or about to undergo surgery and at high risk for a cardiac event or on an opiate or addicted to opiate or with cystic fibrosis or rheumatoid arthritis.Type: GrantFiled: October 25, 2002Date of Patent: September 30, 2003Assignee: Duke UniversityInventors: Jonathan S. Stamler, Robert J. Lefkowitz, Erin J. Whalen, Walter J. Koch, Claude A. Piantadosi
-
Patent number: 6610532Abstract: The present invention relates, in general, to myocardial hypertrophy and, in particular, to agents that inhibit cardiac Gq-coupled receptor signaling and to methods of inhibiting myocardial hypertrophy using same.Type: GrantFiled: July 24, 1998Date of Patent: August 26, 2003Assignee: Duke UniversityInventors: Walter J. Koch, Robert J. Lefkowitz, Shahab A. Akhter, Louis M. Luttrell, Howard Rockman